Payment overview · 2025
General Payments
$701.88
36 reported records · 15 companies
Healthcare provider profile · identity verified
Daniel Edward Banach, MD
Allopathic & Osteopathic Physicians|Family Medicine · PRATTVILLE, AL · NPI 1114913787
Verified facts
What the public records show
CMS Open Payments records show Daniel Edward Banach, MD received $701.88 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.45 | 31.4% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.75 | 14.1% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.51 | 11.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.86 | 9.0% | 3 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $44.93 | 6.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.79 | 4.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.95 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.41 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.11 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.15 | 2.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.05 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.79 | 2.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.63 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.52 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.98 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $701.88 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $146.88 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.42 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.42 | 3 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $44.93 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 28 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 461 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 83 |
| Omeprazole | Omeprazole | 288 | 96 |
| Losartan Potassium | Losartan Potassium | 247 | 79 |
| Gabapentin | Gabapentin | 219 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 69 |
| Lisinopril | Lisinopril | 171 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 55 |
| Trazodone Hcl | Trazodone Hcl | 167 | 59 |
| Metformin Hcl | Metformin Hcl | 161 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 49 |
| Montelukast Sodium | Montelukast Sodium | 136 | 42 |
| Carvedilol | Carvedilol | 134 | 44 |
| Furosemide | Furosemide | 128 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 42 |
| Januvia | Sitagliptin Phosphate | 118 | 28 |
| Meloxicam | Meloxicam | 117 | 54 |
| Potassium Chloride | Potassium Chloride | 117 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 29 |
| Famotidine | Famotidine | 114 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 35 |
| Tramadol Hcl | Tramadol Hcl | 107 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 34 |
| Lorazepam | Lorazepam | 88 | 20 |
| Azithromycin | Azithromycin | 86 | 69 |
| Clonazepam | Clonazepam | 85 | 15 |
| Simvastatin | Simvastatin | 83 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 68 |
| Methylprednisolone | Methylprednisolone | 73 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 28 |
| Glipizide Er | Glipizide | 71 | 24 |
| Jardiance | Empagliflozin | 70 | 19 |
| Ozempic | Semaglutide | 70 | 17 |
| Mounjaro | Tirzepatide | 65 | 16 |
| Ramipril | Ramipril | 65 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Bupropion Xl | Bupropion Hcl | 56 | 19 |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Cefdinir | Cefdinir | 54 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Fluconazole | Fluconazole | 52 | 20 |
| Pregabalin | Pregabalin | 52 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 42 |
| Atenolol | Atenolol | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 31 |
| Nystatin | Nystatin | 47 | 13 |
| Estradiol | Estradiol | 46 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 17 |
| Allopurinol | Allopurinol | 44 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 21 |
| Sertraline Hcl | Sertraline Hcl | 42 | 15 |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 18 |
| Fenofibrate | Fenofibrate | 36 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 11 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Eliquis | Apixaban | 28 | 14 |
| Lactulose | Lactulose | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Colchicine | Colchicine | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Prednisone | Prednisone | 24 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | 11 |
| Finasteride | Finasteride | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $701.88 · 36 records | ABBVIE INC. | CAPLYTA, Da Vinci Surgical System, ELIQUIS, Flector, INSPIRE, KRYSTEXXA, Kerendia, Licart, NURTEC ODT, OTEZLA, Ozempic, RELISTOR, REPATHA, REXULTI, Rybelsus, Symbravo, TONMYA, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, VRAYLAR, XIFAXAN, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error